{"id":172308,"date":"2023-09-19T02:23:10","date_gmt":"2023-09-19T07:23:10","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/09\/the-alzheimers-treatment-landscape-leqembi-vs-donanemab"},"modified":"2023-09-19T02:23:10","modified_gmt":"2023-09-19T07:23:10","slug":"the-alzheimers-treatment-landscape-leqembi-vs-donanemab","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/09\/the-alzheimers-treatment-landscape-leqembi-vs-donanemab","title":{"rendered":"The Alzheimer\u2019s Treatment Landscape: Leqembi vs. Donanemab"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/the-alzheimers-treatment-landscape-leqembi-vs-donanemab2.jpg\"><\/a><\/p>\n<p>With the demise of Roche\u2019s gantenerumab in November 2022, the Alzheimer\u2019s disease space became a two-horse race between Eisai and Biogen\u2019s Leqembi (lecanemab) and Eli Lilly\u2019s donanemab. One, Leqembi, received full FDA approval in July; the other, donanemab, is widely expected to secure the agency\u2019s approval before the end of 2023.<\/p>\n<hr>\n<p>With a potential combined market value of $30 billion, BioSpace takes a deep dive into the Phase III data supporting Eisai and Biogen\u2019s Leqembi and Eli Lilly\u2019s investigational donanemab.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>With the demise of Roche\u2019s gantenerumab in November 2022, the Alzheimer\u2019s disease space became a two-horse race between Eisai and Biogen\u2019s Leqembi (lecanemab) and Eli Lilly\u2019s donanemab. One, Leqembi, received full FDA approval in July; the other, donanemab, is widely expected to secure the agency\u2019s approval before the end of 2023. With a potential combined [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-172308","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/172308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=172308"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/172308\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=172308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=172308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=172308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}